CompletedNCT00922090
Patient-reported benefits of quetiapine extended-release for schizophrenia
About this title
Read the official source — NCT00922090Observational studyAges 18–65South Korea
Understand this study
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Busan and 10 more locationsSee all locations and recruitment
Study information
Study start dateJuly 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 1,494
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Observational
- Intervention type
- Interview / survey / observational
- Study phase
- Not clearly listed
- Locations
- South Korea
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00922090
- Official title
Show the full official title
A Non-interventional Study Evaluating the Clinical Benefit and Effectiveness of Quetiapine Fumarate Extended-Release Tablets (SEROQUEL XRâ) in Subjects With Schizophrenia-An Observational, Multicentric Prospective Study
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Busan · Daegu · Goyang
8 more locations
- Gwangju
- Incheon
- Jeju City
- Kyung Gi
- Kyungju
- Kyungnam
- Namyangju
- Seoul
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
